p) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 63 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 65; or

q) the heavy chain comprises the amino acid sequence of SEQ ID NO: 64 and the light chain comprises the amino acid sequence of SEQ ID NO: 66.

18. A pharmaceutical composition comprising the antibody of any one of the preceding claims.

19. A nucleic acid molecule comprising a polynucleotide sequence that encodes a heavy chain or a light chain of the antibody of any one of claims 1 to 17.

20. The nucleic acid molecule of claim 19, wherein the nucleic acid molecule comprises a first polynucleotide sequence that encodes the heavy chain, and a second polynucleotide sequence that encodes the light chain.

21. The nucleic acid molecule of claim 19 or claim 20, wherein the nucleic acid molecule is a vector.

22. A host cell comprising the nucleic acid molecule of any one of claims 19 to 21.

23. The host cell of claim 22, wherein the host cell comprises a first nucleic acid molecule comprising a polynucleotide sequence that encodes a heavy chain, and a second nucleic acid molecule comprising a polynucleotide sequence that encodes a light chain.

24. The host cell of claim 22, wherein the nucleic acid molecule comprises a first polynucleotide sequence that encodes the heavy chain, and a second polynucleotide sequence that encodes the light chain.

25. A method of producing an antibody of any one of claims 1 to 17 comprising incubating the host cell of claim 23 or claim 24 under conditions sufficient to express the antibody.

26. ~~A method of stimulating endocortical bone formation in a patient, comprising administering an effective amount~~ Use of the pharmaceutical composition of claim 18 in the manufacture of a medicament for stimulating endocortical bone formation in a patient.

27. ~~A method of treating, managing, or preventing a disease or disorder characterized by bone loss in a patient, comprising administering an effective amount~~ Use of the pharmaceutical composition of claim 18 in the manufacture of a medicament for treating, managing, or preventing a disease or disorder characterized by bone loss in a patient.

28. The ~~method~~ use of claim 27, wherein the disease or disorder is osteoporosis.

29. A single unit dosage form comprising the pharmaceutical composition of claim 18.